Clinical trials: Induction Chemotherapy
Alcoholism
Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)
This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics.
- Trial name
- NCT00027079
- Testing
- ondansetron (Zofran), naltrexone (ReVia), Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Chemotherapy-Related Cognitive Impairment
Biomarkers for Chemotherapy Associated Neurotoxicity
To assess if biomarkers can be used to predict early treatment related neurotoxicity in patients with Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) and to inform development of novel interventions.
- Trial name
- BioCAN (NCT05280262)
- Testing
- CogState Test
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- NHS Greater Glasgow and Clyde
Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
The purpose of this study is to provide access to Midostaurin and gather additional safety data on the combination of Midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor…
- Trial name
- AMLFLT3 (NCT02624570)
- Testing
- Midostaurin
- Where
- 44 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Safety and Efficacy
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection，and advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH).
- Trial name
- NCT05008666
- Testing
- Sintilimab, Chidamide, Azacitidine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
This pilot study will attempt to establish the feasibility of using tissue oxygen measurements and the protein, neurofilament light chain (NF-L), as potential biomarkers for chemotherapy-induced peripheral neuropathy (CIPN).
- Trial name
- CIPN (NCT03348956)
- Testing
- EPR Oximetry
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Oral Mucositis
Efficacy of Aleo Vera Use in Prevention and Treatment of Chemotherapy-Induced Oral Mucositis in a Group of Egyptian Children with Acute Leukemia
evaluatation the efficacy of Aleovera in prevention and treatment of chemotherapy-induced oral mucositis in children suffering from acute leukemia in terms of appearance and severity
- Trial name
- NCT06757270
- Testing
- Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
RATIONALE: Vitamin E may prevent peripheral neuropathy caused by chemotherapy in patients with cancer. It is not yet known whether vitamin E is more effective than a placebo in preventing peripheral neuropathy caused by…
- Trial name
- NCT00363129
- Testing
- vitamin E
- Where
- 69 sites in United States
- Volunteers
- 207 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Chemotherapy
Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel
compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis.
- Trial name
- NCT07346677
- Testing
- Sesame Oil, Aloe vera gel, Control
- Volunteers
- 190 people
- Sponsor
- University of Basrah
Oral Mucositis
Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies
The purpose of this study is to determine efficacy and toxicity of recombinant human epidermal growth factor (rhEGF) as a preventive drug of oral mucositis during intensive chemotherapy with stem cell transplantation in patients…
- Trial name
- EGFOM (NCT00845819)
- Testing
- rhEGF + povidone iodine, chlorhexidine, & nystatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Seoul National University Hospital
Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster.
- Trial name
- NCT05520567
- Testing
- Gilteritinib, Venetoclax, Azacitidine
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Drug Abuse, Drug Dependence
Prometa Pharmacotherapy for Methamphetamine Dependence
The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared to placebo for initiating abstinence and for preventing relapse to methamphetamine use in treatment-seeking individuals meeting criteria…
- Trial name
- NCT00260481
- Testing
- Prometa
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Los Angeles
Cannabis Dependence, Marijuana Dependence
Combined Pharmacotherapy for Cannabis Dependency
The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for…
- Trial name
- D-LUCS (NCT01020019)
- Testing
- Dronabinol, Lofexidine
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- New York State Psychiatric Institute
Breast Cancer, TNBC - Triple-Negative Breast Cancer
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.
- Trial name
- HIFU (NCT05491694)
- Testing
- Toripalimab, Epirubicin, High Intensity Focused Ultrasoun
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chemotherapy Induced Nausea and Vomiting
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.
- Trial name
- C-PHONE (NCT00211601)
- Testing
- Disease Management Assessment
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Alopecia, Chemotherapy Effects
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
We would suggest to conduct "VOLUME-2" study, as an extension of the ongoing "VOLUME" study with all subjects already included. After completion of VOLUME study, the study will be directly extend with an "open-label design".
- Trial name
- VOLUME2 (NCT02986412)
- Testing
- CG428
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Samsung Medical Center
Cocaine-Related Disorders
Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine
Cocaine abuse continues to represent a significant public-health concern. Cocaine likely creates its addictive effects by increasing levels of dopamine, a chemical found in the brain.
- Trial name
- NCT00218166
- Testing
- GABA Agonists
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Chemotherapy-Induced Thrombocytopenia
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of…
- Trial name
- NCT05261646
- Testing
- Hetrombopag
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome
- Trial name
- NCT00807768
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 540 sites in United States, South Korea
- Volunteers
- 601 people
- Sponsor
- Gynecologic Oncology Group
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent…
- Trial name
- NCT04223024
- Testing
- CCRT+Nimotuzumab, CCRT alone
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an…
- Trial name
- NCT02557035
- Testing
- Palonosetron, Dexamethasone
- Where
- 76 sites in Belarus, Bosnia and Herzegovina and 7 more
- Volunteers
- 441 people
- Sponsor
- Helsinn Healthcare SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.